Trial Profile

A multicentric, prospective study to assess whether Vascular endothelial growth factor A(VEGF-A) amplification in tumor cells could lead to autocrine/paracrine stimulation of tumor growth beside angiogenesis, potentially identifying a patients subgroup with exceptional responses to ramucirumab

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jun 2019 New trial record
04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2019 Primary endpoint (prevalence of VEGF-A amplification of 1% and 15% among all-comers and exceptional responders) has been met as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com